CXCR

The CXCR signaling pathway family mainly comprises chemokines and chemokine receptors and CXCR consists of about 330 amino acids. The seven transmembrane regions divide the molecule into an extracellular free N-terminus, three extracellular loops, three intracellular loops, and several C-terminal portions. The intracellular second loop is a site that is coupled to a heterotrimeric G-protein and has a characteristic aspartate-arginine-tyrosine box amino acid sequence.

Cat No.	product name
T1739	WZ811	WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
T1776	Plerixafor	Plerixafor, a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
T1776L	AMD 3100 octahydrochloride	AMD 3100 octahydrochloride blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (...
T1955	SB225002	SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
T2477	UNBS-5162	UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
T3047	SRT3109	SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
T3327	Arteether	Arteether is a new, fast-acting antimalarial drug.
T3396	Baohuoside I	Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.
T4032	MSX-127	MSX-127 elicites positive response in peptide CXCR4.
T4033	MSX-130	MSX-130 is CXCR4 Antagonist.
T4163	Repertaxin	Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR...
T6764	ATI-2341	ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to pr...
T3992	MSX-122	MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions(IC50 = 10 nM).
T5193	Danirixin	Danirixin is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM).
T5207	LIT-927	LIT-927 is an orally active CXCL12 neutraligand (Ki: 267 nM for CXCL12 binding to CXCR4).
T7130	Navarixin	Navarixin(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking i...
T5849	JMS-17-2	JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).
T7681	AZD-5069	AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79 nM).
TQ0174	AMD-070	Mavorixafor (AMD-070) is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-t...
T12269L	NUCC-390 dihydrochloride	NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.
T12269	NUCC-390	NUCC-390 is a selective agonist of small-molecule CXCR4 receptor.
T10905	CXCR2-IN-1	CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
T8497	SX-682	SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.
TP2141L	Balixafortide	Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and pro...
T14665	Motixafortide	Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
T12705	Reparixin L-lysine salt	Reparixin L-lysine salt is an allosteric chemokine receptor 1/2 (CXCR1/2) activation inhibitor.
T11140	E6130	E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
T11179	Elubrixin	Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such ...
TP2141	Balixafortide TFA	Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large pan...
T10635	Burixafor hydrobromide	Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in tr...
T19385	ITIC-4F	ITIC-4F has broad applicability in high-efficiency binary and ternary single-junction as well as tandem polymer solar cells (PSCs).ITIC-4F is an indacenodithien...
T19386	ITIC	ITIC has a superior thermal stability and undergoes a glass-crystal transition considerably below its high Tg of 180 °C. ITIC, non-fullerene acceptor, is an in...
T16850	SB-265610	SB-265610 is a nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilizat...
T16864	SCH 563705	SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
T16933	SRT3190	SRT3190 is an antagonist of CXCR2.
T17208	USL311	USL311 is a selective antagonist of CXCR4. USL311 prevents the binding of stromal-cell derived factor-1 to CXCR4.
TN5227	(+/-)-Vestitol	Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential t...